Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

Several other equities research analysts have also recently issued reports on EBS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark boosted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Up 1.2 %

EBS opened at $11.61 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a market cap of $629.19 million, a PE ratio of -2.83 and a beta of 1.60. The company has a 50-day moving average price of $9.39 and a 200 day moving average price of $9.31.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.88. The business had revenue of $293.80 million during the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. Sell-side analysts expect that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Emergent BioSolutions during the 2nd quarter worth approximately $93,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions in the third quarter worth approximately $96,000. FORA Capital LLC acquired a new stake in Emergent BioSolutions during the third quarter worth $103,000. Landscape Capital Management L.L.C. purchased a new stake in Emergent BioSolutions in the third quarter valued at $141,000. Finally, Entropy Technologies LP acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at $155,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.